Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem
PubMed
24213308
DOI
10.1177/0961203313511555
PII: 0961203313511555
Knihovny.cz E-zdroje
- Klíčová slova
- Lupus nephritis, cyclosporine A, systemic lupus erythematosus, treatment,
- MeSH
- cyklofosfamid škodlivé účinky MeSH
- cyklosporin škodlivé účinky MeSH
- imunosupresiva škodlivé účinky MeSH
- lidé MeSH
- následné studie MeSH
- nefritida při lupus erythematodes farmakoterapie patologie MeSH
- proliferace buněk účinky léků MeSH
- randomizované kontrolované studie jako téma metody MeSH
- renální insuficience chemicky indukované patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- cyklofosfamid MeSH
- cyklosporin MeSH
- imunosupresiva MeSH
Objective To evaluate the extended follow-up of the CYCLOFA-LUNE trial, a randomized prospective trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide (CPH) or cyclosporine A (CyA). Patients and methods Data for kidney function and adverse events were collected by a cross-sectional survey for 38 of 40 patients initially randomized in the CYCLOFA-LUNE trial. Results The median follow-up time was 7.7 years (range 5.0-10.3). Rates of renal impairment and end-stage renal disease, adverse events (death, cardiovascular event, tumor, premature menopause) did not differ between the CPH and CyA group, nor did mean serum creatinine, 24 h proteinuria and SLICC damage score at last follow-up. Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs. Conclusion An immunosuppressive regimen based on CyA achieved similar clinical results to that based on CPH in the very long term.
Citace poskytuje Crossref.org